Skip to main content

Advertisement

SpringerLink
Log in

Morphological and immunohistochemical analysis in ovaries and fallopian tubes of tamoxifen, letrozole and clomiphene-treated rats

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Ovarian and tubal dysplasia may be precursors to ovarian cancer. The goal of this study was to check whether these histopathological lesions would be found after ovulation induction using tamoxifen, clomiphene citrate and letrozole.

Methods

Seventy-two rats were divided into four groups. In the first group, 24 rats received normal saline. The second group (16 rats) received clomiphene citrate for six cycles. The third group, divided into two sub-groups of eight rats each, were stimulated with tamoxifen for six cycles, with a dosage, respectively, of 0.4 and 0.8 mg/kg/day. In the last group, eight rats received letrozole 0.1 mg/kg/day and eight other rats received letrozole 0.5 mg/kg/day, for six cycles. Once the six cycles had been completed the rats were killed in order to remove ovaries and tubes for histopathological analysis (morphological, p53 and Ki67 immunohistochemical assessment).

Results

Histopathological lesions were found in both ovaries and tubes. The mean ovarian dysplasia score was significantly higher in the tamoxifen group whatever the dosage (p = 0.006 and 0.0002) and in the letrozole group with 0.5 mg/kg/day (p = 0.0002) compared with the control group. The mean tubal dysplasia score was significantly higher in all groups that received drug treatment compared with the control group, whatever the dosage used. The proliferation index (Ki67) was significantly higher in the tamoxifen and letrozole groups while no significant difference was found for apoptosis marker p53.

Conclusions

Ovulation induction may induce histopathological abnormalities in ovaries and tubes with a different immunohistochemical profile in comparison with salpingo-oophorectomies for genetic risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chene G, Dauplat J, Robin N, Caure A, Penault-Llorca F (2013) Tu-be or tu-be: that is the question… About serous ovarian carcinogenesis. Crit Rev Oncol/Hematol 88:134–143

    Article  CAS  Google Scholar 

  2. Auersperg N (2010) The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol 30:12–21

    Article  Google Scholar 

  3. Deligdisch L, Gil J (1989) Characterization of ovarian dysplasia by interactive morphometry. Cancer 63:748–755

    Article  CAS  PubMed  Google Scholar 

  4. Deligdisch L, Miranda C, Barba J (1993) Ovarian dysplasia: nuclear texture analysis. Cancer 72:3253–3257

    Article  CAS  PubMed  Google Scholar 

  5. Chene G, Penault-Llorca F, Le Bouedec G et al (2009) Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Int J Gynecol Cancer 19:65–72

    Article  PubMed  Google Scholar 

  6. Medeiros F, Muto MG, Lee Y et al (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236

    Article  PubMed  Google Scholar 

  7. Folkins AK, Jarboe EA, Saleemuddin A et al (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109:168–173

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y (2007) Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 5:35–44

    Article  PubMed Central  PubMed  Google Scholar 

  9. Cibula D, Widschwendter M, Majek O, Dusek L (2011) Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Human Reprod update 17:55–67

    Article  CAS  Google Scholar 

  10. Nieto JJ, Crow J, Sundaresan M et al (2001) Ovarian epithelial dysplasia in relation to ovulation induction and nulliparity. Gynecol Oncol 82:344–349

    Article  CAS  PubMed  Google Scholar 

  11. Chene G, Penault-Llorca F, Le Bouedec G et al (2009) Ovarian epithelial dysplasia after ovulation induction: time and dose effect. Human Reprod 24:132–138

    Article  CAS  Google Scholar 

  12. Chene G, Penault-Llorca F, Tardieu A et al (2012) Is there a relationship between ovarian epithelial dysplasia and infertility? Obstet Gynecol Int 2012:429085

    PubMed Central  PubMed  Google Scholar 

  13. Chene G, Raoelfils I, Dauplat J et al (2012) Don’t forget Fallopian tubes: a morphologic and immunohistochemical study about Fallopian tubes with genetic risk (BRCA mutation). Gynecol Obstet Fertil 40:14–18

    Article  CAS  PubMed  Google Scholar 

  14. Brown J, Farquhar C, Beck J, Boothroyd C, Hugues E (2009) Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 4:CD002249

    PubMed  Google Scholar 

  15. Badawy A, Gibreal A (2011) Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS: a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol 159:151–154

    Article  CAS  PubMed  Google Scholar 

  16. Dauplat J, Chene G, Pomel C et al (2009) Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer. Eur J Cancer 45:2977–2983

    Article  CAS  PubMed  Google Scholar 

  17. Schloosshauer PW, Cohen CJ, Penault-Lllorca F, Miranda CR, Bignon YJ, Dauplat J, Deligdisch L (2003) Prophylactic oophorectomy. Cancer 98:2599–2606

    Article  Google Scholar 

  18. Carcangiu ML, Radice P, Manoukian S et al (2003) Atypical epithelial proliferation in Fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA 1 and BRCA 2 germline mutation carriers. Int J Gynecol Pathol 23:35–40

    Article  Google Scholar 

  19. Fathalla M (1971) Incessant ovulation: a factor in ovarian neoplasia? Lancet 2:163

    Article  CAS  PubMed  Google Scholar 

  20. Celik C, Gezginç K, Aktan M et al (2004) Effects of ovulation induction on ovarian morphology: an animal study. Int J Gynecol Cancer 14:600–606

    Article  CAS  PubMed  Google Scholar 

  21. Corakci A, Filiz S, Caliskan E, Dalcik C, Ozeren S, Dalcik H (2005) The effect of ovulation induction on ovarian epithelium dysplasia score and Ki67 expression: an experimental study on rats. Int J Gynecol Cancer 15:866–871

    Article  CAS  PubMed  Google Scholar 

  22. Ozcan Z, Celik H, Gurates B et al (2009) Effects of ovulation induction agents on ovarian surface epithelium in rats. RBM online 19:314–318

    CAS  PubMed  Google Scholar 

  23. Lacoste CR, Clemenson A, Lima S, Lecointre R, Peoc’h M, Chene G (2013) Tubo-ovarian dysplasia in relationship with ovulation induction in rats. Fertil Steril 99:1768–1773

    Article  CAS  PubMed  Google Scholar 

  24. Vicus D, Rosen B, Lubinski J et al (2009) Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecol Oncol 115:135–137

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Swerdlow AJ, Jones ME (2007) Ovarian cancer risk in premenopausal and perimenopausal women treated with tamoxifen: a case-control study. Br J Cancer 96:850–855

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Cohen I, Beyth Y, Tepper R et al (1996) Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol 60:54–58

    Article  CAS  PubMed  Google Scholar 

  27. Spicer DV, Pike MC, Henderson BE (1991) Ovarian cancer and long-term tamoxifen in premenopausal women. Lancet 337:1414

    Article  CAS  PubMed  Google Scholar 

  28. Ting AY, Kimler BF, Fabian CJ, Petroff BK (2008) Tamoxifen prevents premalignant changes of breast, but not ovarian cancer in rats at high risk for both diseases. Cancer Prev Res 1:546–553

    Article  CAS  Google Scholar 

  29. Pickel H, Reich O, Tamussino K (1999) Bilateral atypical hyperplasia of the fallopian tube associated with tamoxifen: a report of two cases. Int J Gynecol Pathol 17:284–285

    Article  Google Scholar 

  30. Diwan BA, Anderson LM, Ward JM (1997) Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen. Carcinogenesis 18:2009–2014

    Article  CAS  PubMed  Google Scholar 

  31. Piek JM, van Diest PJ, Zweemer RP (2001) Dysplastic changes in prophylactic removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451–456

    Article  CAS  PubMed  Google Scholar 

  32. Cirpan T, Terek MC, Ulukus M, Ulukus EC, Akman L, Kanit L (2008) Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovaries and uterus of tamoxifen-treated rats. Int J Gynecol Cancer 18:141–145

    Article  CAS  PubMed  Google Scholar 

  33. Mahdavi A, Pejovic T, Nezhat F (2006) Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 85:819–826

    Article  CAS  PubMed  Google Scholar 

  34. Chene G, Rahimi K, Mes Masson AM, Provencher D (2013) Surgical implications of the potential new tubal pathway for the ovarian carcinogenesis. J Minim Invasive Gynecol 20:153–159

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetric, Gynecology and Reproductive Medicine, CHU Nord, 42000, St Etienne, France

    Suzanne Lima, Claude-Regis Lacoste & Gautier Chene

  2. Department of Histopathology, CHU Nord, 42000, St Etienne, France

    Alix Clemenson & Michel Peoc’h

  3. Department of Medical Information, CHU Nord, 42000, St Etienne, France

    Beatrice Trombert

  4. Department of Pharmacy of Clinical Oncology, Lyon Sud Hospital, 69000, Lyon, France

    Romain Lecointre

  5. Department of Gynecology, HFME, Hospices Civils de Lyon, 69000, Lyon, France

    Gautier Chene

Authors
  1. Suzanne Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alix Clemenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beatrice Trombert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Romain Lecointre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claude-Regis Lacoste
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michel Peoc’h
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gautier Chene
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gautier Chene.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lima, S., Clemenson, A., Trombert, B. et al. Morphological and immunohistochemical analysis in ovaries and fallopian tubes of tamoxifen, letrozole and clomiphene-treated rats. Arch Gynecol Obstet 290, 553–559 (2014). https://doi.org/10.1007/s00404-014-3234-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-014-3234-4

Keywords

Search

Navigation